tirzepatide injection vs semaglutide compounded semaglutide vs semaglutide or

STEP-1: Semaglutide 2,4 mg, the standard since 2021 The STEP-1 trial (Wilding et al., NEJM 2021, PMID 33567185) randomized 1,961 overweight or obese adults (BMI 30 or BMI 27 with comorbidities) without diabetes to semaglutide 2,4 mg/week or placebo, with lifestyle interventions administered concurrently in both arms

Facial swelling, throat tightness, or difficulty breathing (potential anaphylaxis)

The total weekly amount stays the same, but dividing it into two smaller injections reduces the spike in side effects that a single weekly dose can cause

This is a pertinent question that needs to be answered

Semaglutide remains an excellent option, especially for those who tolerate it well

References Share this post Mochi Bites More articles